Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.
about
Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitorsIn vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cellsThe distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses.The role of drug transporters in the kidney: lessons from tenofovirPrevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovirPharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionMTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartmentsMulticompartmental pharmacokinetic model of tenofovir delivery by a vaginal gelAnalytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectivenessGenotoxic and Cytotoxic Effects of Antiretroviral Combinations in Mice Bone MarrowTenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon*Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaquesAntiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human bloodTenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density lossPharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infectionTenofovir disoproxil fumarate.Effect of tenofovir on didanosine absorption in patients with HIV.Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection.Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress.Tenofovir disoproxil fumarate for the treatment of HIV infection.A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns.Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism.Chemoprophylaxis for HIV prevention: new opportunities and new questions.New anti-HIV agents and targets.AIDS vaccines and preexposure prophylaxis: is synergy possible?New approaches in the management of chronic hepatitis B: role of tenofovir.Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.Prevention of perinatal HIV transmission: a review of novel strategies.Timing of the components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals.Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy.Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infantsPre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
P2860
Q24536268-7601A8BB-DF76-4228-B530-9D71851223F7Q24674939-1684611A-C23B-400F-82BB-A7F9AB7812DFQ25257032-96A983DF-E1C7-4AA3-9770-B1D68DF1D184Q26866489-6CC028A9-A0C1-4949-8D2D-FE4401AD6526Q28472146-CB6507EF-02C5-4D86-A150-7F0AE0AFF76CQ28481276-CC9E2757-E22B-4EA7-A9D5-96899F1BFB53Q28485356-2B80729E-420B-4AA7-9628-CB9F074D0969Q28533251-7B052B58-B638-4780-9144-9C75E7F6D86FQ28535414-BF68AC92-68CD-42C5-BE53-926C8A9E87EEQ28553106-1BEB8E78-CF8F-482A-9B3F-20F26C144D17Q28571788-30102414-A2A6-4F09-BCE9-352FA47859D9Q28775900-6CF13A5D-2FD3-4133-A0AF-36B54924DCDDQ31050092-DF798C67-6B24-4554-9B6F-575694FEFE5EQ33460754-3A369D3C-DE10-44A4-B360-D3CE41240CDFQ33690506-14A466AA-C885-40E9-B678-E0B4CF3CE59CQ33759543-4ED4D8FB-6982-402C-A121-CF8D81AA7C32Q33805141-1413EBE1-6364-4440-BF19-F4CB7127E29DQ33883722-BFE6DC07-31E4-406E-A2E8-C197B665E6A4Q33938112-57512FD5-8786-4FFF-A794-7530B4428CB8Q34481359-CE321B40-C021-4AE5-BE3E-7D01F47CB157Q34534058-E6CAB0F6-0752-491A-8FB8-8FE86D9E5502Q34536261-250C8EA8-7246-4AF6-A5DB-99D5E19C32C1Q34544211-978797EF-6D77-4820-B89E-875FE760B35DQ34551836-BB22FF6F-C15C-49B6-84D4-5DAEDFD755F7Q34553539-331E316D-7F71-42A8-8527-142044C8B544Q34569309-7D64D9DC-8498-4F80-8B5B-4995DDB0B731Q34573789-D557B973-710F-4506-BA20-8F02EA89BF2BQ34658079-5EA3CBAC-B6A3-4E88-81E9-AD08F56022D8Q34786284-635BE097-2657-4165-80A4-70036BC2B1E1Q34944447-85368D1A-924E-4021-9FCF-DD4E0CA984BBQ35003539-023F4D72-4B57-42B2-B307-BBB7CA47376BQ35026531-99A03B79-6D2D-432F-BE00-90D79872BED4Q35043368-743BCB4A-CCD2-424A-90C1-F084E6383900Q35103702-6FF2BB7B-5384-41FC-BE70-7D5AE15FBBB6Q35207628-A86CD0CF-5720-46B3-BE68-EC79D048CD3DQ35274822-3195AC88-229C-484B-A615-21B4A80BFEFCQ35331387-D483B9DE-7015-408D-8147-1FE9AFC0D603Q35598502-7B81442D-90BB-41D1-A93D-35C97B694DAAQ35636514-28F35980-5011-4F3F-B22F-385972B92FF2Q35752812-CC831C0B-3E28-4F69-A719-EAF287B15BFA
P2860
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Phase i/ii trial of the pharma ...... iciency virus-infected adults.
@ast
Phase i/ii trial of the pharma ...... iciency virus-infected adults.
@en
type
label
Phase i/ii trial of the pharma ...... iciency virus-infected adults.
@ast
Phase i/ii trial of the pharma ...... iciency virus-infected adults.
@en
prefLabel
Phase i/ii trial of the pharma ...... iciency virus-infected adults.
@ast
Phase i/ii trial of the pharma ...... iciency virus-infected adults.
@en
P2093
P2860
P921
P1476
Phase i/ii trial of the pharma ...... iciency virus-infected adults.
@en
P2093
B P Kearney
D F Coakley
P Barditch-Crovo
P S Lietman
R L Coleman
P2860
P304
P356
10.1128/AAC.45.10.2733-2739.2001
P407
P577
2001-10-01T00:00:00Z